PMID- 32888029
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20210927
IS  - 1349-9157 (Electronic)
IS  - 0449-3060 (Print)
IS  - 0449-3060 (Linking)
VI  - 61
IP  - 6
DP  - 2020 Nov 16
TI  - Safety of total body irradiation using intensity-modulated radiation therapy by 
      helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a 
      prospective pilot study.
PG  - 969-976
LID - 10.1093/jrr/rraa078 [doi]
AB  - Total body irradiation using intensity-modulated radiation therapy total body 
      irradiation (IMRT-TBI) by helical tomotherapy in allogeneic hematopoietic stem 
      cell transplantation (allo-HSCT) allows for precise evaluation and adjustment of 
      radiation dosage. We conducted a single-center pilot study to evaluate the safety 
      of IMRT-TBI for allo-HSCT recipients. Patients with hematological malignancies in 
      remission who were scheduled for allo-HSCT with TBI-based myeloablative 
      conditioning were eligible. The primary endpoint was the incidence of adverse 
      events (AEs). Secondary endpoints were engraftment rate, overall survival, 
      relapse rate, non-relapse mortality, and the incidence of acute and chronic 
      graft-versus-host disease (aGVHD and cGVHD, respectively). Between July 2018 and 
      November 2018, ten patients were recruited with a median observation duration of 
      571 days after allo-HSCT (range, 496-614). D80% for planning target volume (PTV) 
      in all patients was 12.01 Gy. Average D80% values for lungs, kidneys and lenses 
      (right/left) were 7.50, 9.03 and 4.41/4.03 Gy, respectively. Any early AEs 
      (within 100 days of allo-HSCT) were reported in all patients. Eight patients 
      experienced oral mucositis and gastrointestinal symptoms. One patient experienced 
      Bearman criteria grade 3 regimen-related toxicity (kidney and liver). All cases 
      achieved neutrophil engraftment. There was no grade III-IV aGVHD or late AE. One 
      patient died of sinusoidal obstruction syndrome 67 days after allo-HSCT. The 
      remaining nine patients were alive and disease-free at final follow-up. Thus, 
      IMRT-TBI was well tolerated in terms of early AEs in adult patients who underwent 
      allo-HSCT; this warrants further study with longer observation times to monitor 
      late AEs and efficacy.
CI  - (c) The Author(s) 2020. Published by Oxford University Press on behalf of The 
      Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
FAU - Konishi, Tatsuya
AU  - Konishi T
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Ogawa, Hiroaki
AU  - Ogawa H
AD  - Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan 
      Cancer and Infectious Diseases Center, Komagome Hospital.
FAU - Najima, Yuho
AU  - Najima Y
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Hashimoto, Shinpei
AU  - Hashimoto S
AD  - Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan 
      Cancer and Infectious Diseases Center, Komagome Hospital.
FAU - Wada, Atsushi
AU  - Wada A
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Adachi, Hiroto
AU  - Adachi H
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Konuma, Ryosuke
AU  - Konuma R
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Kishida, Yuya
AU  - Kishida Y
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Nagata, Akihito
AU  - Nagata A
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Yamada, Yuta
AU  - Yamada Y
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Kaito, Satoshi
AU  - Kaito S
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Mukae, Junichi
AU  - Mukae J
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Marumo, Atsushi
AU  - Marumo A
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Noguchi, Yuma
AU  - Noguchi Y
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Toya, Takashi
AU  - Toya T
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Igarashi, Aiko
AU  - Igarashi A
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Kobayashi, Takeshi
AU  - Kobayashi T
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Ohashi, Kazuteru
AU  - Ohashi K
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Doki, Noriko
AU  - Doki N
AD  - Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, 
      Komagome Hospital.
FAU - Karasawa, Katsuyuki
AU  - Karasawa K
AD  - Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan 
      Cancer and Infectious Diseases Center, Komagome Hospital.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Radiat Res
JT  - Journal of radiation research
JID - 0376611
SB  - IM
MH  - Adult
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - *Patient Safety
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Radiotherapy, Intensity-Modulated/*methods
MH  - Recurrence
MH  - Remission Induction
MH  - Transplantation Conditioning
MH  - Treatment Outcome
MH  - Whole-Body Irradiation/*methods
MH  - Young Adult
PMC - PMC7674702
OTO - NOTNLM
OT  - allogeneic stem cell transplantation
OT  - helical tomotherapy
OT  - intensity-modulated radiation therapy
OT  - total body irradiation
EDAT- 2020/09/06 06:00
MHDA- 2021/09/28 06:00
PMCR- 2020/09/05
CRDT- 2020/09/05 05:19
PHST- 2020/05/11 00:00 [received]
PHST- 2020/07/05 00:00 [revised]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/09/06 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2020/09/05 05:19 [entrez]
PHST- 2020/09/05 00:00 [pmc-release]
AID - 5901557 [pii]
AID - rraa078 [pii]
AID - 10.1093/jrr/rraa078 [doi]
PST - ppublish
SO  - J Radiat Res. 2020 Nov 16;61(6):969-976. doi: 10.1093/jrr/rraa078.